Biotricity, Inc., medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated electrocardiogram (ECG) device and software solution. The company is based in Redwood City, California.
IPO Year:
Exchange: NASDAQ
Website: biotricity.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | Buy → Neutral | H.C. Wainwright | |
| 3/7/2022 | $5.00 | Buy | Lake Street |
| 11/23/2021 | $6.00 | Buy | HC Wainwright & Co. |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright downgraded Biotricity from Buy to Neutral
Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00
HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00
10-Q - BIOTRICITY INC. (0001630113) (Filer)
10-K - BIOTRICITY INC. (0001630113) (Filer)
NT 10-K - BIOTRICITY INC. (0001630113) (Filer)
10-Q/A - BIOTRICITY INC. (0001630113) (Filer)
10-Q - BIOTRICITY INC. (0001630113) (Filer)
NT 10-Q - BIOTRICITY INC. (0001630113) (Filer)
8-K - BIOTRICITY INC. (0001630113) (Filer)
10-Q - BIOTRICITY INC. (0001630113) (Filer)
25-NSE - BIOTRICITY INC. (0001630113) (Subject)
10-Q - BIOTRICITY INC. (0001630113) (Filer)
Fastest customizable press release news feed in the world
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e
Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid
FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q
REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev
Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p
Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn
Company expects to report Q3-FY25 revenue growth of 22% from the corresponding prior year quarter to $3.6 million – an 11% increase sequentially from the immediately preceding quarterManagement continues to drive recurring revenue growth and efficienciesCompany to report positive cash flow for Q3-FY25 on current operating basis, before interest, dividends and amortizationCompany to report improved gross margins and operating results, as the Company nears its goal of achieving profitabilityManagement to release full financial results on Wednesday February 19th and host its Q3 Fiscal Year 2025 Financial Results Call on Thursday February 20th at 5:30 PM EST. REDWOOD CITY, Calif., Feb. 17, 202
REDWOOD CITY, Calif. and BELFAST, Northern Ireland, Jan. 15, 2025 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY), a provider of remote cardiac monitoring solutions, and B-Secur, a leader in biosensing technology, have joined forces to create one of the most advanced, device-neutral platforms for integrated heart monitoring. By combining B-Secur's HeartKey® technology, a suite of FDA-cleared algorithms and analytics, with Biotricity's medical and consumer diagnostic solutions, the new partnership will empower Integrated Delivery Networks, healthcare providers, health systems, and
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without any need for future financing. REDWOOD CITY, Calif., Dec. 27, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced that it has completed a series of financings that bolster the Company's financial health, reduce execution risk, and provide it with the necessary resources to achieve profitability. Company has all the
Live finance-specific insights
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e
Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid
FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q
REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev
Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p
Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn
Company expects to report Q3-FY25 revenue growth of 22% from the corresponding prior year quarter to $3.6 million – an 11% increase sequentially from the immediately preceding quarterManagement continues to drive recurring revenue growth and efficienciesCompany to report positive cash flow for Q3-FY25 on current operating basis, before interest, dividends and amortizationCompany to report improved gross margins and operating results, as the Company nears its goal of achieving profitabilityManagement to release full financial results on Wednesday February 19th and host its Q3 Fiscal Year 2025 Financial Results Call on Thursday February 20th at 5:30 PM EST. REDWOOD CITY, Calif., Feb. 17, 202
REDWOOD CITY, Calif. and BELFAST, Northern Ireland, Jan. 15, 2025 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY), a provider of remote cardiac monitoring solutions, and B-Secur, a leader in biosensing technology, have joined forces to create one of the most advanced, device-neutral platforms for integrated heart monitoring. By combining B-Secur's HeartKey® technology, a suite of FDA-cleared algorithms and analytics, with Biotricity's medical and consumer diagnostic solutions, the new partnership will empower Integrated Delivery Networks, healthcare providers, health systems, and
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without any need for future financing. REDWOOD CITY, Calif., Dec. 27, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced that it has completed a series of financings that bolster the Company's financial health, reduce execution risk, and provide it with the necessary resources to achieve profitability. Company has all the
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
3 - BIOTRICITY INC. (0001630113) (Issuer)
3 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)
SC 13G - BIOTRICITY INC. (0001630113) (Subject)